ArticleThe American journal of gastroenterology2019
Early Detection of Pancreatic Cancer in High-Risk Individuals: Where Do We Go From Here?
Article in The American journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate on Computed Tomography.Gut and liver · 2022Article
- Artificial intelligence and imaging for risk prediction of pancreatic cancer: a narrative review.Chinese clinical oncology · 2022Review
- Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images.Frontiers in oncology · 2022Article
- Predicting pancreatic ductal adenocarcinoma using artificial intelligence analysis of pre-diagnostic computed tomography images.Cancer biomarkers : section A of Disease markers · 2022Article
- A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.Nature reviews. Clinical oncology · 2020Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
Pancreatic cancer is a lethal disease that is commonly diagnosed at a late stage. Screening asymptomatic patients is necessary for early detection, but this is not currently recommended in the general population. As demonstrated in the current study, an important number of patients at increased risk can be diagnosed using either MRI/magnetic resonance cholangiopancreatography or endoscopic ultrasound. Further collaborative efforts are needed to define the ideal population for testing and refine the current approach to pancreatic cancer surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.